A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Trial Profile

A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Ofatumumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms RESONATE
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 25 Jun 2017 Updated results presented at the 22nd Congress of the European Haematology Association.
    • 06 Jun 2017 4-year follow-up results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 Long-term efficacy and safety results were presented at 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) according to an Abbvie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top